Search research articles
Contact Us
Filters
Showing results (301-310 of 353) with videos related to
Page
of 36
Sort By:
JAMA Network Open
|
May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial
Arun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study
Cristian Udovicich, Mathias Bressel, Jamil Manji, et al.
The Lancet. Oncology
|
October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew J Martin, Louise Emmett, et al.
European Urology Focus
|
May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Edmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
K N Chi, T Kheoh, C J Ryan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Prostate Cancer and Prostatic Diseases
|
January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
H H Cheng, R Gulati, A Azad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 11, 2024
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T
James P Buteau, Louise Kostos, Ramin Alipour, et al.
Nature Communications
|
September 2, 2023
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models
L H Porter, J J Zhu, N L Lister, et al.
Clinical Genitourinary Cancer
|
April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study
J Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
Page
of 36
Search research articles
Search
Showing results (301-310 of 353) with videos related to
Sort By:
Page
of 36
JAMA Network Open
|
May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial
Arun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study
Cristian Udovicich, Mathias Bressel, Jamil Manji, et al.
The Lancet. Oncology
|
October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew J Martin, Louise Emmett, et al.
European Urology Focus
|
May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Edmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
K N Chi, T Kheoh, C J Ryan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.
Prostate Cancer and Prostatic Diseases
|
January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
H H Cheng, R Gulati, A Azad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 11, 2024
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T
James P Buteau, Louise Kostos, Ramin Alipour, et al.
Nature Communications
|
September 2, 2023
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models
L H Porter, J J Zhu, N L Lister, et al.
Clinical Genitourinary Cancer
|
April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study
J Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
Page
of 36